Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3)

被引：1
|
作者：
Matsuyama, Jin
Kurokawa, Yukinori
Nishikawa, Kazuhiro
Kimura, Yutaka
Takeno, Atsushi
Kawada, Junji
Kawabata, Ryohei
Makari, Youichi
Tamura, Shigeyuki
Doki, Yuichiro
Sakai, Daisuke
Shimokawa, Toshio
Satoh, Taroh
机构：
[1] Yao Municipal Hosp, Yao, Japan
[2] Osaka Univ, Grad Sch Med, Osaka, Japan
[3] Osaka Natl Hosp, Osaka, Japan
[4] Kindai Univ, Osaka, Japan
[5] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan
[6] Kaizuka City Hosp, Osaka, Japan
[7] Osaka Rosai Hosp, Sakai, Osaka, Japan
[8] Sakai City Med Ctr, Sakai, Osaka, Japan
[9] Wakayama Med Univ, Wakayama, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.119
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
119
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical study of docetaxel plus S-1 as neoadjuvant therapy for advanced gastric cancer
    Yuxiao Chai
    Yu Han
    Bing Wang
    Yi Zhang
    Xinglong Qu
    Oncology and Translational Medicine, 2016, 2 (02) : 80 - 83
  • [22] A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer
    Toshikazu Moriwaki
    Shinji Hirai
    Shuichi Hironaka
    Kenji Amagai
    Atsuko Soeda
    Mikio Sato
    Takeshi Nihei
    Mitsuaki Hirose
    Kenji Matsuda
    Atsushi Ohkawara
    Taketo Yamaguchi
    Mitsuharu Ozeki
    Takashi Mamiya
    Tetsuya Murashita
    Ichinosuke Hyodo
    Gastric Cancer, 2014, 17 : 354 - 361
  • [23] Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin
    Nishikawa, Kazuhiro
    Yamada, Yasuhide
    Ishido, Kenji
    Gotoh, Masahiro
    Bando, Hideaki
    Sugimoto, Naotoshi
    Nishina, Tomohiro
    Amagai, Kenji
    Chin, Keisho
    Niwa, Yasumasa
    Tsuji, Akihito
    Imamura, Hiroshi
    Tsuda, Masahiro
    Yasui, Hirofumi
    Fujii, Hirofumi
    Yamaguchi, Kensei
    Yasui, Hisateru
    Hironaka, Shuichi
    Shimada, Ken
    Miwa, Hiroto
    Hamada, Chikuma
    Hyodo, Ichinosuke
    GASTRIC CANCER, 2017, 20 (04) : 640 - 645
  • [24] A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer
    Moriwaki, Toshikazu
    Hirai, Shinji
    Hironaka, Shuichi
    Amagai, Kenji
    Soeda, Atsuko
    Sato, Mikio
    Nihei, Takeshi
    Hirose, Mitsuaki
    Matsuda, Kenji
    Ohkawara, Atsushi
    Yamaguchi, Taketo
    Ozeki, Mitsuharu
    Mamiya, Takashi
    Murashita, Tetsuya
    Hyodo, Ichinosuke
    GASTRIC CANCER, 2014, 17 (02) : 354 - 361
  • [25] Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin
    Kazuhiro Nishikawa
    Yasuhide Yamada
    Kenji Ishido
    Masahiro Gotoh
    Hideaki Bando
    Naotoshi Sugimoto
    Tomohiro Nishina
    Kenji Amagai
    Keisho Chin
    Yasumasa Niwa
    Akihito Tsuji
    Hiroshi Imamura
    Masahiro Tsuda
    Hirofumi Yasui
    Hirofumi Fujii
    Kensei Yamaguchi
    Hisateru Yasui
    Shuichi Hironaka
    Ken Shimada
    Hiroto Miwa
    Chikuma Hamada
    Ichinosuke Hyodo
    Gastric Cancer, 2017, 20 : 640 - 645
  • [26] Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013).
    Yamada, Yasuhide
    Boku, Narikazu
    Mizusawa, Junki
    Iwasa, Satoru
    Kadowaki, Shigenori
    Nakayama, Norisuke
    Azuma, Mizutomo
    Sakamoto, Takeshi
    Shitara, Kohei
    Okuno, Tatsuya
    Chin, Keisho
    Nozaki, Akira
    Nakamura, Masaki
    Hara, Hiroki
    Katayama, Hiroshi
    Fukuda, Haruhiko
    Yoshikawa, Takaki
    Sano, Takeshi
    Sasako, Mitsuru
    Terashima, Masanori
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer
    Kang, Yoon-Koo
    Kim, Hyung-Don
    Cho, Hyungwoo
    Park, Young Soo
    Lee, Jong Seok
    Ryu, Min-Hee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [28] Randomized phase II study of S-1/CDDP plus TSU-68 versus S-1/CDDP in patients with advanced gastric cancer
    Yamaguchi, Kensei
    Koizumi, Wasaburo
    Hosaka, Hisashi
    Takinishi, Yasutaka
    Nakayama, Norisuke
    Hara, Takuo
    Muro, Kei
    Baba, Hideo
    Sasaki, Yasutsuna
    Nishina, Tomohiro
    Fuse, Nozomu
    Esaki, Taito
    Takagi, Masakazu
    Gotoh, Masahiro
    Kitamura, Ryuichi
    Matsumoto, Hideki
    Sasaki, Tsuneo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [29] A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
    Lee, Keun-Wook
    Kim, Bum Jun
    Kim, Mi-Jung
    Han, Hye Sook
    Kim, Jin Won
    Park, Young Lee
    Park, Sook Ryun
    CANCER RESEARCH AND TREATMENT, 2017, 49 (03): : 706 - 716
  • [30] A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine
    Kim, B.
    Lee, K. W.
    Kim, M. J.
    Han, H. S.
    Park, Y. L.
    Park, S. R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S432 - S432
12345